

References

I-209

1. S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences. (2019). Genetic and Rare Diseases (GARD) Information Center. Updated 09/11/2017.
2. Micromedex DrugDex Compendium®.2023. Emapalumab-lzsg.

Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc.Emapalumab-lzsg.
3. Gamifant™ (emapalumab-lzsg) injection, for intravenous use [package insert]. Sobi, Inc. Waltham, MA. Revised 05/2022.
4. Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. *Medicine*. 2018;97(31):1-9.
5. Jordan MB. Emergence of targeted therapy for hemophagocytic lymphohistiocytosis.*American Society of Hematology*. 2018;15(2):1-8.
6. Louder DT, Bin Q, de Min C, et al. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. *Blood Advances*. 2019; 3(1):47-50.
7. Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. *Blood*. 2019;134(21):1783-1786.
8. Al-Salama ZT. Emapalumab: first global approval. *Drugs*. 2019;79(99): 103-108.
9. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. *N Engl J Med*.2020; 382(19):1811-1822.
10. Emapalumab-lzsg In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 12/20/2018.

11. Merli P, Algeri M, Gaspari S, Locatelli F. Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL). *Immunol.* 11:608492. doi:10.3389/fimmu.2020.608492